Previous 10 | Next 10 |
Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference PR Newswire LA JOLLA, Calif. , April 7, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Gainers: Sigma Labs (SGLB) +162%.Check-Cap (CHEK) +110%.Rubius Therapeutics (RUBY) +69%.Luokung Technology (LKCO) +43%.Shaw Communications (SJR) +38%.RumbleON (RMBL) +38%.Aeterna Zentaris (AEZS) +31%.Baosheng Media (BAOS) +30%.Intec Pharma (NTEC) +29%.GenMark Diagnostics (GNMK)...
Torchlight Energy Resources (TRCH) -15% on business combination timingRubius Therapeutics (RUBY) -14% on initial data for RTX-240 in solid tumorsEntera Bio (ENTX) -13%.Nova LifeStyle (NVFY) -12%.NLS Pharmaceutics (NLSP) -12%.Eli Lilly and Company (LLY) -7% after ...
Gainers: NLS Pharmaceutics NLSP +111%, Entera Bio ENTX +75%, Seelos Therapeutics SEEL +34%, Regulus Therapeutics (RGLS) +27%, Rafael (RFL) +27%.Losers: Marker Therapeutics MRKR -28%, Timber Pharmaceuticals (TMBR) -21%, Evoke Pharma EVOK...
Regulus Therapeutics (RGLS): Q4 EPS of -$0.03 may not be comparable to consensus of -$0.14.Revenue of $5M (4Q19 : $0.02M).Cash and cash equivalents of $31.1M.Press Release For further details see: Regulus Therapeutics EPS of -$0.03
Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates Completed Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD") Closed $19...
Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire LA JOLLA, Calif. , March 5, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and dev...
Regulus Therapeutics (RGLS) soars 18% after completing enrollment of the first cohort of patients into its Phase 1b clinical study of RGLS4326.The study is designed to evaluate the safety, pharmacokinetics, and changes in levels of polycystin 1 (PC1) and polycystin 2 (PC2) in patien...
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire LA JOLLA, Calif. , Feb. 10, 2021 /PRNewswire/ -- R...
AMC Entertainment Holdings (AMC) +240%.Koss Corporation (KOSS) +117%.Express (EXPR) +91%.GameStop (GME) +55%.Vislink Technologies (VISL) +22% as shipping of Satellite communications equipment begins.Revlon (REV) +16%.J.Jill (JILL) +17%.Accelerate Diagnostics (AXDX) +17%.Pitney ...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...